Kornimate/medical-research-clean huggingface dataset:
the nationwide real-world status of oral corticosteroid use in patients with asthma

Conditions: Asthma; Corticosteroid

Summary: the health insurance review and assessment service (hira) database contains nationwide claim data. by utilizing this database, the investigators aimed to analyze the current status of ocs use in south korea by using hira database.

south korea has a compulsory universal health insurance system for entire korean population. the number of people who are covered was more than 50 million. the health insurance review and assessment service (hira) database contains nationwide claim data. by utilizing this database, the investigators have performed many studies regarding asthma in south korea. in this study, the investigators aimed to analyze the current status of ocs use in south korea by using hira database. primary outcome was the ocs prescription in all patients with asthma. secondary outcome was ocs prescription according to the asthma severity, age, sex, socioeconomic status and the type of hospital. inclusion criteria was 1) age ≥ 15 years; 2) icd-10 codes for asthma (j45.x-j46) as the primary or within fourth secondary diagnosis; 3) use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (lama), long acting beta2 agonist (laba), ics, ics+laba, short acting muscarinic antagonist (sama), short acting beta2 agonist (saba), sama+saba, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).

Eligibility criteria:
inclusion criteria: * age ≥ 15 years; * icd-10 codes for asthma (j45.x-j46) as the primary or within fourth secondary diagnosis * use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (lama), long acting beta2 agonist (laba), ics, ics+laba, short acting muscarinic antagonist (sama), short acting beta2 agonist (saba), sama+saba, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist). exclusion criteria: • those who are not in the insurance system
the occurrence of atrial fibrillation after totally endoscopic cardiac surgery

Conditions: Atrial Fibrillation

Summary: the aim of this study is to investigate the occurrence of new-onset postoperative atrial fibrillation after totally endoscopic cardiac surgery.


Eligibility criteria:
inclusion criteria: * \>18 years old * patients undergoing elective endoscopic cardiac surgery (totally endoscopic coronary artery bypass grafting or endoscopic valve replacement) exclusion criteria: * preoperative atrial fibrillation * patients that do not understand dutch or french or english * patients that do not have a smartphone * concomitant or redo surgeries

Keywords: postoperative atrial fibrillation minimally invasive cardiac surgery
a study to evaluate the safety, tolerability, and efficacy of a197 in subjects with dry eye disease

Conditions: Dry Eye Disease

Summary: the objectives of this trial are to assess the safety, tolerability and efficacy of a197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with dry eye disease.


Eligibility criteria:
inclusion criteria: * written informed consent must be obtained prior to any study-related assessments * have a history of dry eye disease in both eyes for at least 12 months prior to visit 1 * willing and able to follow instructions and can be present for required study visits exclusion criteria: * women who are pregnant or breastfeeding * use of topical ophthalmic medications, artificial tears, eye drops and gels in either eye * use of contact lenses within 90 days prior to visit 1 and throughout the study * have had an ocular infection in either eye within 90 days prior to visit 1
etoposide plus lobaplatin versus etoposide plus cisplatin for patients with limited small-cell lung cancer

Conditions: Small-cell Lung Cancer

Summary: this randomized phase ii study compare survival outcomes and toxicity of two chemotherapy regimens (etoposide plus lobaplatin or etoposide plus cisplatin) in combination with concurrent thoracic radiation therapy (trt) for limited stage small cell lung cancer.

lobaplatin is a platinum complex with dna alkylating activity that was developed by asta medica (degussa) for the treatment of cancer. lobaplatin as the third-generation platinum antineoplastic agent, showed promising antineoplastic effects in variety of preclinical test tumor models. a randomized, multicenter phase iii study showed that lobaplatin plus etoposide (el) regimen is not inferiority to cisplatin plus etoposide (ep) regimen in terms of pfs, the tolerance and qol with el regimen are better than that with ep regimen. thus, we perform this study was to compare the efficacy and safety of el and ep regimens concurrently with thoracic radiotherapy in patients with limited-stage sclc.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed sclc * newly diagnosed sclc * either sex, age between 18 to 75 years * limited stage: ajcc (8th edition) stage i-iii (t any, n any, m0) that can be safely treated with definitive radiation doses. excludes t3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. * performance status ecog grade 0-1. patients with ps 2 whose general condition is explained by obstructive/bulky disease likely to improve after the first cycle of chemotherapy can be included at the discretion of the local investigator. patients with ps 2 as a result of comorbid conditions will be excluded. * adequate bone marrow, liver and renal function as defined below:neutrophils ≥ 1.5 × 109/l, platelets 80 × 109/l, hemoglobin ≥80 g/l, ast and alt ≤2× the upper limit of the institutional normal range, total bilirubin ≤1.25× the upper limit of the institutional normal range, and creatinine concentration ≤120 μmol/l * no history of thoracic surgery, radiation therapy, or chemotherapy * had measurable or assessable disease exclusion criteria: * pregnancy or lactation at the time of enrollment * previous malignancy or other concomitant malignant disease * malignant pleural or pericardial effusions
evaluation of the safety and performance of the very high power-short duration qdot

Conditions: Atrial Fibrillation

Summary: the aim of the present study is to compare the safety and short-term performance between thermocool smarttouch sf-5d qdot system used with fast ablation mode and the standard thermocool smartouch sf in treatment of patients with atrial fibrillation (af).

the very high power-short duration (vhpsd) catheter, is a novel cf catheter optimized for temperature-controlled ablation with microelectrodes and 6 thermocouples for real-time temperature monitoring during ablation. the associated vhpsd algorithm modulates power to maintain target temperature during these vhpsd lesions (90 w, 4 s). in preclinical models, vhpsd ablation with this novel catheter has improved atrial linear lesion contiguity, transmurality, and durability and has substantially reduced radiofrequency ablation times, but with a safety profile similar to those of standard irrigated radiofrequency ablation catheters. the qdot -fast study demonstrated the clinical feasibility and safety of vhpsd ablation. procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters. the aim of the present study is to compare the safety and short-term performance between thermocool smarttouch sf-5d qdot system used with fast ablation mode and the standard thermocool smartouch sf in treatment of patients with atrial fibrillation (af).

Eligibility criteria:
inclusion criteria: * male and female \>18 years old. * subjects must provide written informed consent to participate in the study. * subject is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluations. exclusion criteria: * pregnant women. * patients with iodine contrast media allergy * patients with renal failure (gfr \<60ml/min)
temporomandibular dysfunction in patients with tinnitus: assessment and treatment

Conditions: Tinnitus, Subjective

Summary: tmd treatment, based on state of the art knowledge derived from clinical studies will be applied in patients with tinnitus and tmd. when this approach proves to be useful for the treatment of tinnitus, it offers a new therapeutic option for patients with tinnitus. to understand how tmd treatment works for patients with tinnitus, we will analyse mediating factors, i.e. factors that contribute to the therapeutic effect. to help clinicians in their clinical process we will identify prognostic indicators, i.e. factors that predict a positive or negative outcome of tmd treatment. this can provide a helpful tool in clinical practice.


Eligibility criteria:
inclusion criteria: * patients will be included when suffering from somatic tinnitus, attributed to tmd, which has been stable for at least 3 months. * tinnitus functional index score between 25 and 90 exclusion criteria: * clear otological or neurological causes of the tinnitus such as menière's disease, severe depression (diagnosed by a psychologist), progressive middle ear pathology, intracranial pathology * traumatic cervical spine or temporomandibular injury in the past 6 months * tumours * previous surgery in the orofacial area * in case physical therapy treatment directed to the orofacial area is contra-indicated * if the patient received tmd treatment in the past 2 months * drug intake that can affect the outcome measures
deep brain stimulation (dbs) of the nucleus basalis of meynert (nbm) in patients with parkinson's disease

Conditions: Cognitive Deficit

Summary: the existing dbs setting in patients with dbs of the globus pallidus interna (gpi), which aims to treat motor symptoms by a high-frequency stimulation, will be temporarily reprogramed to stimulate the nbm at a low frequency using the distal electrodes positioned in the vicinity of the nbm. this study aims to investigate the neuropsychological effect of low frequency stimulation of the nucleus basalis of meynert (nbm) in advanced parkinson's disease (pd) patients, who were previously treated with deep brain stimulation (dbs) of the globus pallidus interna (gpi).

the existing dbs setting in patients with gpi dbs, which aims to treat motor symptoms by a high-frequency stimulation, will be temporarily reprogramed to stimulate the nbm at a low frequency using the distal electrodes positioned in the vicinity of the nbm.this study consists of a three-day screening study of the nbm stimulation followed by a two-week, randomized, single-blind, crossover trial. between the screening study and the crossover trial, one week of washout period will be applied to eliminate potential carryover effect from the previous stimulation. this study aims to investigate the neuropsychological effect of low frequency stimulation of the nucleus basalis of meynert (nbm) in advanced parkinson's disease (pd) patients, who were previously treated with deep brain stimulation (dbs) of the globus pallidus interna (gpi).

Eligibility criteria:
inclusion criteria: * patients with gpi stimulation, with the nbm within the vicinity of the electric field of at least one dbs electrode. * patients should be able to give informed consent * patients should be on a stable medication regimen for at least 4 weeks exclusion criteria: * any unstable internal disease * subject with significant worsening of motor function during the pilot screening study, which is indicated by an increase of the updrs part iii score more than 30%, will not continue to the crossover trial
qing'e formula therapy on menopausal symptoms (healthy volunteers recruitment for control study)

Conditions: Healthy

Summary: this study will recruit 50 healthy women with normal menstrual cycles aged 40-50, to investigate the expression of their nei network and urine metabolomics.


Eligibility criteria:
inclusion criteria: 1. healthy women with normal menstrual cycles aged 40-50. 2. the score of kupperman index is less than 15. 3. not alcoholics or smokers (past or smoking). 4. get subjects informed consent process should comply with gcp requirements. exclusion criteria: 1. volunteers with heart, liver, kidney disease or acute or chronic gastrointestinal diseases, or with diseases of blood, endocrine, neurological and other systems. 2. volunteers are participating in other clinical trials within 3 months. 3. volunteers who donated blood or loosed blood heavily within 3 months. 4. volunteers with previous history of mental illness, drug abuse or drug dependence. 5. volunteers who took drugs within 14 days before the trail.

Keywords: healthy normal menstrual cycles
effects of mobile application dexteria fine motor skills on hand dexterity and grip strength in chronic stroke patients

Conditions: Stroke, Ischemic; Skill, Social; Occlusion

Summary: to determine the effects of mobile application dexteria fine motor skills on hand dexterity and grip strength in chronic stroke patients

this study will be conducted to investigate the effects of mobile applications of dexterity fine motor skills on hand dexterity and grip strength in chronic stroke patients. data will be collected from jinnah hospital lahore and riphah rehabilitation center lahore. all 22 patients will be taken using random sampling. both study groups will be given common treatment of conventional hand function. the subjects will randomly assign to the experiment group with mobile apps training and the control group without mobile app training. mobile applications like dexteria, scribblekid, peglight and bowling game will be used for the purpose of training and success rate will be considered as outcome measure. test and tools include the nine hole peg test (nhpt), the fugl-meyer motor assessment (fma), the box \& block test (bbt), and grip strength will be assessed using a hand dynamometer. spss 25 version will be used for data entry and analysis.

Eligibility criteria:
inclusion criteria: * six months to 2 years post stroke * participants must be able to open and close their fingers (even only 2 cm of movement) * before stroke there must be fully functional hand * normal or intact vision exclusion criteria: * neurological disorders other than stroke for example multiple sclerosis or parkinson disease. * upper extremities acute orthopaedic conditions. * any cardiopulmonary complications * medically unstable patients.

Keywords: stroke, ischemic skill, social occlusion
study of anlotinib in patients with small cell lung cancer (alter1202)

Conditions: Small Cell Lung Cancer

Summary: to compare the effects and safety of anlotinib with placebo in patients with small cell lung cancer(sclc).


Eligibility criteria:
inclusion criteria: * histological documentation of small cell lung cancer * advanced small cell lung cancer who had at least two chemotherapy regimens,at least one measurable lesion (by recist1.1) * 18-75 years,ecog ps:0-2,life expectancy of more than 3 months * main organs function is normal * women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped * patients should participate in the study voluntarily and sign informed consent exclusion criteria: * patients who have been used anlotinib * patients who have been used targeted drugs(such as sunitinib,bevacizumab,endostar),immune targeted drugs * 4 weeks or less from the last cytotoxic therapy, radiation therapy or surgery * patients whose primary lesion with active bleeding within 4 months * carcinomatous meningitis * patients who known to the central nervous system * patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.) * patients with any severe and/or unable to control diseases，including： 1. blood pressure unable to be controlled ideally(systolic pressure≥150 mmhg，diastolic pressure≥100 mmhg); 2. patients with grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including qtc≥450ms(male),qtc≥470ms（female）) and patients with grade 1 or higher congestive heart failure (nyha classification); 3. patients with active or unable to control serious infections; 4. patients with cirrhosis, decompensated liver disease, or active hepatitis; 5. patients with poorly controlled diabetes (fasting blood glucose(fbg)\>10mmol/l) 6. urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed; * patients with non-healing wounds or fractures * patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism * patients with drug abuse history and unable to get rid of or patients with mental disorders * imaging showed tumors have involved important blood vessels or by investigators determine likely during the follow-up study and cause fatal hemorrhage * history of immunodeficiency * patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
exhaled nitric oxide and airway caliber in children with asthma

Conditions: Asthma in Children

Summary: the purpose of this study is to assess if in steroid naïve asthmatic children with elevated baseline exhaled nitric oxide, treatment with inhaled steroid and normalization of exhaled nitric oxide level results in restoration of the bronchodilator response to deep inhalation.

previous studies have shown that a deep inhalation (di) would increase airway caliber in normal subjects. whereas in asthmatics with spontaneous bronchoconstriction (obstruction of the airway), di was shown to worsen airway obstruction. the mechanism for this variability in response to di is not well-understood, but seems to be a key in understanding the pathophysiology of the disease, and possibly in the development of an effective therapy. air way inflammation resulting in airway wall thickening and peribronchial edema is thought to play a role how the airway responds to deep inhalation. this study assess if reduction in airway inflammation (as measured by level of exhaled no)results in optimization of the bronchodilator response to deep inhalation

Eligibility criteria:
inclusion criteria: * age: \> 6 years at age of screening. * physician diagnosed asthma * elevated exhaled no at initial evaluation (\>25ppb) * be able to reproducibly perform di maneuvers and all other pulmonary function testing * be clinically stable for at least 2 weeks prior to screening with no evidence of acute upper or lower respiratory infection or current pulmonary exacerbation. * has not been on inhaled or oral steroid for at least 4 weeks prior to enrollment in the study. * parent/child willingness to enroll in the study and provide written informed consent. * be able to present for the required study visits. exclusion criteria: * chest wall or spinal column deformity; known cardiac, neuromuscular, or other chronic diseases * use of beta agonist, theophylline, leukotriene receptor antagonists, or caffeine-containing soft drinks 12 hr prior to the study. * use of inhaled steroid in the past 4 weeks. * respiratory infection or asthma exacerbation in the previous 2 weeks

Keywords: asthma deep inhalation exhaled nitric oxide
rectus sheath block: postoperative analgesia and proinflammatory cytokines

Conditions: Postoperative Pain

Summary: good quality of postoperative analgesia would lead to attenuate or prevent the adverse effects on the common functions of the immune system. we compared the effect of epidural analgesia versus rectus sheath block on postoperative pain and proinflammatory cytokines following malignant urological surgery.

study groups: 60 patients were included in the study randomly allocated into two groups of 30 patients. rectus sheath group (rsb): each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia. control group: the patients did not receive any intervention after anaesthesia induction.

Eligibility criteria:
inclusion criteria: male patients their age over 40 years, classified asa i, ii or iii, undergoing radical resection of cancer prostate, through midline abdominal incision under general anaesthesia. exclusion criteria: contraindications to rectus sheath block as patient refusal, coagulopathy, local infection and allergy to bupivacaine. planned transverse or oblique abdominal incision, extensive existing midline abdominal scarring or pre-existing chronic abdominal pain.

Keywords: rectus sheath block, postoperative pain,tnf alpha and il-6
recreational futsal for controlled hypertension

Conditions: Hypertension,Essential; Hypertension; Blood Pressure Disorders; Blood Pressure

Summary: arterial hypertension (ht) was the leading global contributor for premature deaths in 2015. its treatment includes medication and lifestyle changes, namely diet and regular exercise, which has shown to have an inverse relationship with arterial ht. recreational soccer (rs) has proven to be a non-pharmacological treatment for several chronic conditions, including arterial ht, with meaningful decreases on blood pressure (bp). recreation futsal (rf) is expected to elicit comparable bp changes to rs considering that it imposes similar physical and physiological demands. however, the effects of rf on bp and other cardiovascular markers have not been previously investigated in participants only with controlled arterial ht. furthermore, acute bp changes and double product elicited by this exercise modality were never described. therefore, the main purpose of this study is to assess if rf is an effective coadjuvant intervention for bp control in adults with controlled arterial ht. secondary purposes are: i) to determine the impact of rf on other cardiovascular markers; ii) to describe the acute bp changes and the double product elicited by rf; and iii) to assess the impact of 1 month of detraining on bp and other cardiovascular markers (4 months).

statistical analysis: the efficacy of the intervention will be assessed by comparing the differences between groups at follow-up, adjusted for the outcome baseline values, systolic blood pressure, maximum oxygen consumption and age (ancova). intention-to-treat approach will be the main analysis. the missing data will be imputed by using multiple linear regression. a per protocol analysis will also be performed (intervention group: attendance of at least 62.5% of the training sessions; control group: participants that did not engage in regular and supervised physical exercise or had an increase in dose or number of antihypertensive medication). the significance level will be set at 5%. randomization: stratified by baseline systolic blood pressure and maximum oxygen consumption. contingency plan: if the recruitment rate is below than expected, potential measures are to include: i) 30-35- and 60-65-year-old participants; ii) participants with pre-hypertension or uncontrolled hypertension.

Eligibility criteria:
inclusion criteria: * medicated controlled hypertension, with habitual sbp below 140 mmhg and dbp below 90 mmhg; * males with 35-60 years; * not being engaged in regular and supervised physical exercise in the last 6 months; * medical clearance; * vaccinated against sars-cov-2. exclusion criteria: * cardiovascular disease (heart failure), cerebrovascular disease, advanced retinopathy or kidney failure; * resistant hypertension; * history of cardiovascular event.

Keywords: futsal controlled hypertension recreational futsal soccer football